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Abstaining from tobacco smoking is likely to lower the risk of respiratory infections and pneumonia. Unfortunately,
quitting smoking is not easy. Electronic cigarettes (ECs) are emerging as an attractive long-term alternative nicotine
source to conventional cigarettes and are being adopted by smokers who wish to reduce or quit cigarette
consumption. Also, given that the propylene glycol in EC aerosols is a potent bactericidal agent, switching from
smoking to regular vaping is likely to produce additional lung health benefits. Here, we critically address some of
the concerns arising from regular EC use in relation to lung health, including respiratory infections and pneumonia.
In conclusion, smokers who quit by switching to regular ECs use can reduce risk and reverse harm from tobacco
smoking. Innovation in the e-vapour category is likely not only to further minimise residual health risks, but also to
maximise health benefits.
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e-vapourCigarette smoking is a known risk factor for pneumo-
nia, with the risk increasing according to the intensity
of smoking [1, 2]. A dose–response effect of cigarette
smoking upon pneumonia risk has been reported in
several studies, and summarised in a recent review [3].
The increased susceptibility to infection with a variety
of bacterial and viral pathogens appears to be second-
ary to the harmful effect of tobacco smoke upon innate
and adaptive immunity [4]. Undoubtedly, quitting
smoking is among the most important steps smokers
can take to lower the risk of respiratory infections and
pneumonia. Indeed, ex-smokers have a lower risk of
pneumonia than current smokers, irrespective of age
[1, 2, 5]. Smoking is a difficult addiction to break with
many smokers persisting in tobacco use for several
years, and typically cycling through multiple periods of
remission and relapse [6]. This is not surprising given
the powerful addictive qualities of nicotine and non-* Correspondence: polosa@unict.it
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therapy combined with behavioural smoking cessation
support may double or triple quit rates [8], but efficacy
rates, obtained in the context of rigorous randomised
controlled trials, are not replicated in real-life, with dis-
appointingly low cessation rates of about 4–5 % [9–11].
Electronic cigarettes (ECs) are consumer products con-
sisting of a battery and a heating element (atomiser). Puff-
ing on an EC heats up an element (the coil within the
atomiser) that vapourises a solution (e-liquid) mainly con-
sisting of propylene glycol, vegetable glycerin, distilled
water, and flavourings that may or may not contain li-
quid nicotine. ECs are an attractive long-term alterna-
tive nicotine source to conventional cigarettes because
of their many similarities with smoking behaviour [12,
13]. ECs come in a large variety of designs, shapes and
sizes, some resembling conventional tobacco cigarettes
(“cigalikes” ECs), others often resembling a pen (“pen-
like” ECs); however, most experienced users prefer
more advanced designs that bear little visual resem-
blance to conventional cigarettes and allow customisa-
tion (e.g. larger-capacity batteries with adjustable power
delivery, specific heating coils and multiple wickticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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shows that smokers are now ready for this alternative
form of smoking with the aim of reducing cigarette con-
sumption, and to relieve tobacco withdrawal symptoms
[12, 13]. Recent internet-based surveys [14, 15] and clin-
ical trials [16, 17] confirm that ECs may help smokers to
reach these goals.
In itself, abstaining from tobacco smoking by switch-
ing to ECs is likely to lower the risk of respiratory in-
fections and pneumonia. Also, given that propylene
glycol in its aerosol form is a potent bactericidal agent
[18], regular vaping may have additional theoretical
health benefits. Despite the good safety profile of pro-
pylene glycol, a hypersensitivity response to propylene
glycol aerosols may occur in predisposed individuals.
Propylene glycol is a common but often unrecognised
cause of allergic contact dermatitis due to cosmetic
products [19] and direct exposure to propylene glycol
has been reported to cause signs and symptoms of irri-
tation compatible with contact dermatitis around the
mouth or in the oral mucosa of EC users [20]. Only
one study (to date) models the interaction between EC
aerosol emissions and susceptibility to airway infection.
Sussan et al. [21] exposed mice to EC vapour for
2 weeks, followed by pneumococcal infection. EC-
exposed animals had increased pneumococcal colony
forming unit counts in both the airway and lung tissue.
There are several problems with the design of the study
and the authors’ interpretation of the results. The mice
in the experimental group were exposed to a much
higher level of stress than the control group, and stress
affects bacterial and viral response. Moreover, the ex-
perimental conditions exposed the animals to signifi-
cant nicotine poisoning, with an average cotinine
concentration of 267 ng/ml. Cotinine is the primary
metabolite of nicotine and in humans the amount of
nicotine needed to give similar cotinine levels are toler-
ated by heavy smokers, but highly aversive to non-
smokers, who would be expected to feel sick and vomit
at this level of exposure. Mice are much more sensitive
to nicotine than humans (lethal dose in mice is 3 mg/
kg, in humans it is 6.5–13 mg/kg) [22]. The observed
accelerated weight loss, reduced immunity and early
death in the experimental group were more likely the
result of protracted stress and nicotine poisoning.
These interesting findings in rodents do not corrob-
orate the evidence in humans. Despite millions of regu-
lar EC users, there has been no evidence of new
emerging pneumonia outbreaks in recent years, or re-
ports of infectious pneumonia in the medical literature.
However, we are aware of a case of lipoid pneumonia
that respiratory physicians in the United States have
suggested being a direct consequence of vaping [23].
Lipoid pneumonia is a rare respiratory illness that mayoccur from aspiration or inhalation of fatlike material
in the lung; an occurrence that is commonly reported
in elderly people after accidental ingestion of oil-based
laxatives. The assertion that vaping could put people at
risk of lipoid pneumonia is illogical, simply because
commercially available e-liquids do not contain nor
generate fatlike material. A more plausible cause for
this patient’s lipoid pneumonia was the acute exposure
to fumigation chemicals, which may contain crude es-
sential oils.
Another area of concern is that of flavouring-induced
lung disease. Food flavourings are safe to eat, but we
don’t know whether that will also be true if they are in-
haled. For example, diacetyl is a compound commonly
used in the food industry that gives food a buttery taste.
However, chronic exposure to high levels of this fla-
vouring substance in microwave popcorn workers has
been shown to cause the development of bronchiolitis
obliterans, (“popcorn lung”) [24, 25]. Thus, it is of con-
cern that many brands of vaping liquids may contain
varying concentrations of diacetyl (particularly in nutty
flavours) [26, 27]. Nonetheless, there is no report that
this has caused bronchiolitis obliterans in EC users. It
must be noted that cigarette smoke also contains diace-
tyl, but at a much higher level (up to 750 times higher)
than those produced by ECs [28]. And yet there is no
evidence that cigarette smoking causes bronchiolitis
obliterans.
It has also been suggested that vaping may produce an
aerosol of ultrafine particles, which could have negative
effects on the lung health of bystanders [29]. However, it
is not the size that is important, but the composition of
the particle that matters; ultrafine particles are known to
be generated in large quantities when boiling water [30],
but water vapour particles are not harmful to the re-
spiratory system. Particles emitted from ECs have com-
pletely different physical (they are liquid droplets) and
chemical (they have hardly any of the toxic properties)
properties compared to environmental pollution or
cigarette smoke [31]. Most importantly, passive vaping
cannot be compared to passive smoking, because ECs do
not have a substantial negative impact on indoor air
quality given that – by design – they do not generate
side-stream emissions [32]. Finally, there are no studies
indicating that particles emitted from ECs represent a
risk factor for bystanders.
Considering that vapour toxicology is by far less
problematic than that of conventional cigarettes [29],
that e-vapour products are at least 96 % less harmful
compared to combustible cigarettes [33] and that
cigarette smoking carries a heightened risk for respira-
tory infections and pneumonia [1–4], substantially re-
ducing daily cigarette consumption in smokers by
switching to e-vapour products is likely to produce
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sidual risks will be further diminished by adopting new
technologies and applying quality and safety standards.
ECs will be soon regulated by the new Tobacco Prod-
ucts Directive (TPD) of the European Parliament and
the Council of the European Union [34], which man-
dates that e-vapour products are only placed on the
market if the nicotine dose and uptake is reported on
the unit packet and toxicological risk assessment is car-
ried out on aerosol emissions.
Fast innovation in the e-vapour category is likely not
only to further minimise residual health risks, but also
to maximise health benefits in regular EC users. For ex-
ample, by exploiting different product designs, we are
now beginning to learn that adoption rates (and conse-
quently the extent of reduction in tobacco consumption)
are strongly associated with their efficiency as smoking
cessation products, where smoking cessation is the main
“collateral benefit” for many smokers switching to regu-
lar EC use [35–37]. Future research will have to quantify
the extent of achievable reduction of the risk when
switching to regular EC use. These research endeavors,
together with the emerging positive evidence in EC users
with preexisting airway diseases [38], may consolidate
the notion that smokers who quit smoking by switching
to ECs can reverse harm from tobacco smoking in the
lung [39]. This should be taken into consideration by
regulatory authorities seeking to adopt proportional
measures for the e-vapour category [40].
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